Does the media favor FDMT or CMPX?

In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than Compass Therapeutics. MarketBeat recorded 13 mentions for 4D Molecular Therapeutics and 6 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 0.89 beat 4D Molecular Therapeutics' score of 0.09 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LXRX or CMPX?

In the previous week, Compass Therapeutics had 3 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 6 mentions for Compass Therapeutics and 3 mentions for Lexicon Pharmaceuticals. Compass Therapeutics' average media sentiment score of 0.89 beat Lexicon Pharmaceuticals' score of 0.42 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, IMMX or CMPX?

Immix Biopharma is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.88 N/A Compass Therapeutics N/A N/A -$66.49M -$0.40 N/A

Is IMMX or CMPX more profitable?

Immix Biopharma's return on equity of -38.44% beat Compass Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -38.44% -34.72% Compass Therapeutics N/A -38.71% -34.72%

Does the media prefer IMMX or CMPX?

In the previous week, Compass Therapeutics had 3 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for Compass Therapeutics and 3 mentions for Immix Biopharma. Compass Therapeutics' average media sentiment score of 0.89 beat Immix Biopharma's score of 0.41 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, SLDB or CMPX?

Solid Biosciences is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.91 N/A Compass Therapeutics N/A N/A -$66.49M -$0.40 N/A

Is SLDB or CMPX more profitable?

Compass Therapeutics' return on equity of -38.71% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -71.35% -60.58% Compass Therapeutics N/A -38.71% -34.72%

Does the media favor SLDB or CMPX?

In the previous week, Compass Therapeutics had 3 more articles in the media than Solid Biosciences. MarketBeat recorded 6 mentions for Compass Therapeutics and 3 mentions for Solid Biosciences. Compass Therapeutics' average media sentiment score of 0.89 beat Solid Biosciences' score of 0.40 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Compass Therapeutics (CMPX) Competitors

$0.99 +0.01 (+0.98%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.01 +0.02 (+1.61%)

As of 10/9/2026 07:59 PM Eastern

Compare

CMPX vs. GERN, FDMT, LXRX, IMMX, and SLDB

Should you buy Compass Therapeutics stock or one of its competitors? Compass Therapeutics's main competitors and comparable companies include Geron (GERN), 4D Molecular Therapeutics (FDMT), Lexicon Pharmaceuticals (LXRX), Immix Biopharma (IMMX), and Solid Biosciences (SLDB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Compass Therapeutics compare to Geron?

Geron (NASDAQ:GERN) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, Compass Therapeutics had 5 more articles in the media than Geron. MarketBeat recorded 6 mentions for Compass Therapeutics and 1 mentions for Geron. Compass Therapeutics' average media sentiment score of 0.89 beat Geron's score of 0.76 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Geron	Positive
Compass Therapeutics	Positive

73.7% of Geron shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Compass Therapeutics has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Compass Therapeutics	N/A	-38.71%	-34.72%

Geron has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

Compass Therapeutics has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.28	-$83.50M	-$0.11	N/A
Compass Therapeutics	N/A	N/A	-$66.49M	-$0.40	N/A

Geron presently has a consensus price target of $4.00, suggesting a potential upside of 226.53%. Compass Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 932.23%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Compass Therapeutics	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76

Summary

Compass Therapeutics beats Geron on 11 of the 16 factors compared between the two stocks.

How does Compass Therapeutics compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

4D Molecular Therapeutics has a beta of 2.75, meaning that its stock price is 175% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

Compass Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. Compass Therapeutics' return on equity of -38.71% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
Compass Therapeutics	N/A	-38.71%	-34.72%

Compass Therapeutics has lower revenue, but higher earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	8.64	-$140.11M	-$2.63	N/A
Compass Therapeutics	N/A	N/A	-$66.49M	-$0.40	N/A

4D Molecular Therapeutics presently has a consensus target price of $28.90, suggesting a potential upside of 116.80%. Compass Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 932.23%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Compass Therapeutics	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than Compass Therapeutics. MarketBeat recorded 13 mentions for 4D Molecular Therapeutics and 6 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 0.89 beat 4D Molecular Therapeutics' score of 0.09 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Therapeutics beats 4D Molecular Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Compass Therapeutics compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Lexicon Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

In the previous week, Compass Therapeutics had 3 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 6 mentions for Compass Therapeutics and 3 mentions for Lexicon Pharmaceuticals. Compass Therapeutics' average media sentiment score of 0.89 beat Lexicon Pharmaceuticals' score of 0.42 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lexicon Pharmaceuticals currently has a consensus price target of $5.70, suggesting a potential upside of 239.29%. Compass Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 932.23%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Compass Therapeutics	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76

Compass Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Lexicon Pharmaceuticals' return on equity of -37.53% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
Compass Therapeutics	N/A	-38.71%	-34.72%

Lexicon Pharmaceuticals has higher revenue and earnings than Compass Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	15.01	-$50.34M	-$0.15	N/A
Compass Therapeutics	N/A	N/A	-$66.49M	-$0.40	N/A

Summary

Compass Therapeutics beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Compass Therapeutics compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Immix Biopharma's return on equity of -38.44% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-38.44%	-34.72%
Compass Therapeutics	N/A	-38.71%	-34.72%

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Compass Therapeutics had 3 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for Compass Therapeutics and 3 mentions for Immix Biopharma. Compass Therapeutics' average media sentiment score of 0.89 beat Immix Biopharma's score of 0.41 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immix Biopharma presently has a consensus price target of $24.14, indicating a potential upside of 155.21%. Compass Therapeutics has a consensus price target of $10.25, indicating a potential upside of 932.23%. Given Compass Therapeutics' higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Compass Therapeutics	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76

Immix Biopharma is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
Compass Therapeutics	N/A	N/A	-$66.49M	-$0.40	N/A

Immix Biopharma has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

Summary

Compass Therapeutics beats Immix Biopharma on 9 of the 13 factors compared between the two stocks.

How does Compass Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Solid Biosciences is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Compass Therapeutics	N/A	N/A	-$66.49M	-$0.40	N/A

Solid Biosciences has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Compass Therapeutics had 3 more articles in the media than Solid Biosciences. MarketBeat recorded 6 mentions for Compass Therapeutics and 3 mentions for Solid Biosciences. Compass Therapeutics' average media sentiment score of 0.89 beat Solid Biosciences' score of 0.40 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences currently has a consensus target price of $18.69, suggesting a potential upside of 172.09%. Compass Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 932.23%. Given Compass Therapeutics' higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Compass Therapeutics	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76

Compass Therapeutics' return on equity of -38.71% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Compass Therapeutics	N/A	-38.71%	-34.72%

Summary

Compass Therapeutics beats Solid Biosciences on 10 of the 13 factors compared between the two stocks.

Get Compass Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPX vs. The Competition

Export

Metric	Compass Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$177.10M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-2.48	13.42	274.15	26.16
Price / Sales	N/A	1,237.85	590.48	94.54
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	0.89	17.17	11.21	6.34
Net Income	-$66.49M	-$22.69M	$3.50B	$381.90M
7 Day Performance	15.91%	-1.33%	-0.90%	-1.41%
1 Month Performance	-51.56%	-8.44%	-4.44%	-3.48%
1 Year Performance	-76.58%	14.02%	6.96%	1.16%

Compass Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPX Compass Therapeutics	4.3614 of 5 stars	$0.99 +1.0%	$10.25 +932.2%	-75.6%	$177.10M	N/A	N/A	39
GERN Geron	2.5585 of 5 stars	$1.25 -0.8%	$4.00 +220.0%	-11.9%	$809.52M	$183.88M	N/A	258
FDMT 4D Molecular Therapeutics	3.4646 of 5 stars	$14.56 +0.6%	$28.56 +96.1%	+39.4%	$799.38M	$85.21M	N/A	196	News Coverage Analyst Forecast Insider Trade
LXRX Lexicon Pharmaceuticals	2.5131 of 5 stars	$1.90 +5.8%	$5.70 +200.0%	+2.4%	$798.70M	$49.80M	N/A	81	High Trading Volume
IMMX Immix Biopharma	2.893 of 5 stars	$11.47 +4.6%	$22.86 +99.3%	+266.7%	$784.79M	N/A	N/A	21

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPX) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Therapeutics (CMPX) Competitors

CMPX vs. GERN, FDMT, LXRX, IMMX, and SLDB

How does Compass Therapeutics compare to Geron?

Summary

How does Compass Therapeutics compare to 4D Molecular Therapeutics?

Summary

How does Compass Therapeutics compare to Lexicon Pharmaceuticals?

Summary

How does Compass Therapeutics compare to Immix Biopharma?

Summary

How does Compass Therapeutics compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX vs. The Competition

Compass Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Therapeutics (CMPX) Competitors

CMPX vs. GERN, FDMT, LXRX, IMMX, and SLDB

How does Compass Therapeutics compare to Geron?

Does the media refer more to GERN or CMPX?

Do institutionals & insiders hold more shares of GERN or CMPX?

Is GERN or CMPX more profitable?

Which has more volatility & risk, GERN or CMPX?

Which has stronger earnings and valuation, GERN or CMPX?

Do analysts prefer GERN or CMPX?

Summary

How does Compass Therapeutics compare to 4D Molecular Therapeutics?

Which has more risk & volatility, FDMT or CMPX?

Is FDMT or CMPX more profitable?

Which has higher earnings and valuation, FDMT or CMPX?

Do analysts recommend FDMT or CMPX?

Do institutionals and insiders hold more shares of FDMT or CMPX?

Does the media favor FDMT or CMPX?

Summary

How does Compass Therapeutics compare to Lexicon Pharmaceuticals?

Which has more risk and volatility, LXRX or CMPX?

Does the media favor LXRX or CMPX?

Do insiders and institutionals hold more shares of LXRX or CMPX?

Do analysts rate LXRX or CMPX?

Is LXRX or CMPX more profitable?

Which has better valuation & earnings, LXRX or CMPX?

Summary

How does Compass Therapeutics compare to Immix Biopharma?

Is IMMX or CMPX more profitable?

Do institutionals and insiders believe in IMMX or CMPX?

Does the media prefer IMMX or CMPX?

Do analysts rate IMMX or CMPX?

Which has better valuation and earnings, IMMX or CMPX?

Which has more risk & volatility, IMMX or CMPX?

Summary

How does Compass Therapeutics compare to Solid Biosciences?

Which has preferable valuation and earnings, SLDB or CMPX?

Which has more volatility & risk, SLDB or CMPX?

Do insiders & institutionals hold more shares of SLDB or CMPX?

Does the media favor SLDB or CMPX?

Do analysts rate SLDB or CMPX?

Is SLDB or CMPX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX vs. The Competition

Compass Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools